Full metadata record
DC FieldValueLanguage
dc.contributor.authorHuang, Szu-Weien_US
dc.contributor.authorLi, Wei-Youen_US
dc.contributor.authorWang, Wen-Hungen_US
dc.contributor.authorLin, Yu-Tingen_US
dc.contributor.authorChou, Chih-Hungen_US
dc.contributor.authorChen, Marceloen_US
dc.contributor.authorHuang, Hsien-Daen_US
dc.contributor.authorChen, Yen-Hsuen_US
dc.contributor.authorLu, Po-Liangen_US
dc.contributor.authorWang, Sheng-Fanen_US
dc.contributor.authorOka, Shinichien_US
dc.contributor.authorChen, Yi-Ming Arthuren_US
dc.date.accessioned2017-04-21T06:55:11Z-
dc.date.available2017-04-21T06:55:11Z-
dc.date.issued2017-01-20en_US
dc.identifier.issn1932-6203en_US
dc.identifier.urihttp://dx.doi.org/10.1371/journal.pone.0170420en_US
dc.identifier.urihttp://hdl.handle.net/11536/133027-
dc.description.abstractThe usefulness of ultra-deep pyrosequencing (UDPS) for the diagnosis of HIV-1 drug resistance (DR) remains to be determined. Previously, we reported an explosive outbreak of HIV-1 circulating recombinant form (CRF) 07_BC among injection drug users (IDUs) in Taiwan in 2004. The goal of this study was to characterize the DR of CRF07_BC strains using different assays including UDPS. Seven CRF07_BC isolates including 4 from early epidemic (collected in 2004 - 2005) and 3 from late epidemic (collected in 2008) were obtained from treatment-naive patient\'s peripheral blood mononuclear cells. Viral RNA was extracted directly from patient\'s plasma or from cultural supernatant and the pol sequences were determined using RT-PCR sequencing or UDPS. For comparison, phenotypic drug susceptibility assay using MAGIC-5 cells (in-house phenotypic assay) and Antivirogram were performed. In-house phenotypic assay showed that all the early epidemic and none of the late epidemic CRF07_BC isolates were resistant to most protease inhibitors (PIs) (4.4 - 47.3 fold). Neither genotypic assay nor Antivirogram detected any DR mutations. UDPS showed that early epidemic isolates contained 0.01 +/- 0.08% of PI DR major mutations. Furthermore, the combinations of major and accessory PI DR mutations significantly correlated with the phenotypic DR. The in-house phenotypic assay is superior to other conventional phenotypic assays in the detection of DR variants with a frequency as low as 0.01%.en_US
dc.language.isoen_USen_US
dc.titleCharacterization of the Drug Resistance Profiles of Patients Infected with CRF07_BC Using Phenotypic Assay and Ultra-Deep Pyrosequencingen_US
dc.identifier.doi10.1371/journal.pone.0170420en_US
dc.identifier.journalPLOS ONEen_US
dc.citation.volume12en_US
dc.citation.issue1en_US
dc.contributor.department生物科技學系zh_TW
dc.contributor.department生物資訊及系統生物研究所zh_TW
dc.contributor.departmentDepartment of Biological Science and Technologyen_US
dc.contributor.departmentInstitude of Bioinformatics and Systems Biologyen_US
dc.identifier.wosnumberWOS:000392405300131en_US
Appears in Collections:Articles